Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice
- 1 May 2000
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 85 (10) , 46-52
- https://doi.org/10.1016/s0002-9149(00)00906-1
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmiasThe American Journal of Cardiology, 2000
- Generic substitution and optimal patient care.Archives of internal medicine (1960), 1999
- Generic Antiarrhythmic Drugs: What Constitutes EquivalencyJournal of Interventional Cardiac Electrophysiology, 1999
- Pharmacological Effects of Antiarrhythmic DrugsArchives of internal medicine (1960), 1998
- Individual BioequivalenceClinical Pharmacokinetics, 1997
- Drug Product Selection-Part 3: The Orange BookAmerican Pharmacy, 1991
- Generic substitutions for antiepileptic drugsNeurology, 1990
- Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamideThe American Journal of Cardiology, 1989
- A simple method of monitoring antiarrhythmic drugs during short- and long-term therapyThe American Journal of Cardiology, 1989
- Analysis of antiarrhythmic drug concentrations determined during electrophysiologic drug testing in patients with inducible tachycardiasThe American Journal of Cardiology, 1988